Print this page    •   Back to Web version of article

Policy & Politics
Aurobindo Pharma Receives Tentative FDA Approval to Produce Generic Antiretroviral Stavudine for PEPFAR

July 5, 2005

FDA on Friday granted tentative approval to Indian drug manufacturer Aurobindo Pharma to produce the generic antiretroviral stavudine for use under the President's Emergency Plan for AIDS Relief, Reuters reports. Stavudine, manufactured by Bristol-Myers Squibb under the brand name Zerit, is used in combination with other antiretrovirals to treat HIV infection (Reuters, 7/1). HHS in May 2004 announced plans for a new FDA fast-track review program to speed the delivery of low-cost antiretroviral drugs -- including fixed-dose combination drugs -- to nations covered under PEPFAR. The expedited process is meant to encourage drug makers to produce generic medications to improve access to drugs in remote areas of severely affected countries and ensure the drugs' safety (Kaiser Daily HIV/AIDS Report, 6/21). The tentative approval designation means the generic drug meets FDA safety and efficacy standards but cannot be sold in the United States because of existing patents or exclusivity agreements. HHS Secretary Mike Leavitt said in a statement, "We are pleased to announce another completed drug review by HHS and the administration in our continuing efforts to make available safe and effective AIDS treatments," adding, "Stavudine is another treatment in the expanding arsenal in the global fight against AIDS" (FDA release, 7/1).

Back to other news for July 5, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.




This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art8920.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.